{"name":"Ache Laboratorios Farmaceuticos S.A.","slug":"ache-laboratorios-farmaceuticos-s-a","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"oncology","drugs":[{"name":"Recombinant human growth hormone - Hormotrop","genericName":"Recombinant human growth hormone - Hormotrop","slug":"recombinant-human-growth-hormone-hormotrop","indication":"Other","status":"marketed"},{"name":"Recombinant human growth hormone - Biomatrop","genericName":"Recombinant human growth hormone - Biomatrop","slug":"recombinant-human-growth-hormone-biomatrop","indication":"Other","status":"marketed"},{"name":"Combodart®","genericName":"Combodart®","slug":"combodart","indication":"Benign prostatic hyperplasia with lower urinary tract symptoms","status":"phase_3"},{"name":"DNN.22.17.036","genericName":"DNN.22.17.036","slug":"dnn-22-17-036","indication":"Other","status":"marketed"},{"name":"Motore","genericName":"Motore","slug":"motore","indication":"Other","status":"marketed"},{"name":"Placebo (for Voltaren)","genericName":"Placebo (for Voltaren)","slug":"placebo-for-voltaren","indication":"Control arm in Phase 3 clinical trial for Voltaren (diclofenac) indication","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"cardiovascular","drugs":[{"name":"glucosamine sulfate /chondroitin sulfate - capsules","genericName":"glucosamine sulfate /chondroitin sulfate - capsules","slug":"glucosamine-sulfate-chondroitin-sulfate-capsules","indication":"Osteoarthritis, particularly knee osteoarthritis","status":"phase_3"},{"name":"glucosamine sulfate /chondroitin sulfate - sachet","genericName":"glucosamine sulfate /chondroitin sulfate - sachet","slug":"glucosamine-sulfate-chondroitin-sulfate-sachet","indication":"Osteoarthritis","status":"phase_3"},{"name":"Candicort®","genericName":"Candicort®","slug":"candicort","indication":"Inflammatory and pruritic dermatological conditions (e.g., eczema, dermatitis, psoriasis)","status":"phase_3"},{"name":"Cosamin DS®","genericName":"Cosamin DS®","slug":"cosamin-ds","indication":"Osteoarthritis pain and joint function","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"neuroscience","drugs":[{"name":"Baycuten N®","genericName":"Baycuten N®","slug":"baycuten-n","indication":"Inflammatory skin conditions with secondary bacterial infection or infection risk (e.g., eczema, dermatitis, impetigo)","status":"phase_3"},{"name":"Canesten®","genericName":"Canesten®","slug":"canesten","indication":"Vaginal candidiasis","status":"marketed"},{"name":"Nizoral®","genericName":"Nizoral®","slug":"nizoral","indication":"Seborrheic dermatitis (topical formulation)","status":"marketed"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"brompheniramine + phenylephrine","genericName":"brompheniramine + phenylephrine","slug":"brompheniramine-phenylephrine","indication":"Allergic rhinitis with nasal congestion","status":"marketed"},{"name":"Brompheniramine + pseudoephedrine","genericName":"Brompheniramine + pseudoephedrine","slug":"brompheniramine-pseudoephedrine","indication":"Allergic rhinitis with nasal congestion","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"infectious","drugs":[{"name":"Product CM9241GRU","genericName":"Product CM9241GRU","slug":"product-cm9241gru","indication":"Hypertension","status":"phase_3"},{"name":"Product DNN.65.21.005","genericName":"Product DNN.65.21.005","slug":"product-dnn-65-21-005","indication":"Type 2 diabetes","status":"phase_3"}]}],"pipeline":[{"name":"Recombinant human growth hormone - Hormotrop","genericName":"Recombinant human growth hormone - Hormotrop","slug":"recombinant-human-growth-hormone-hormotrop","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Recombinant human growth hormone - Biomatrop","genericName":"Recombinant human growth hormone - Biomatrop","slug":"recombinant-human-growth-hormone-biomatrop","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"brompheniramine + phenylephrine","genericName":"brompheniramine + phenylephrine","slug":"brompheniramine-phenylephrine","phase":"marketed","mechanism":"Brompheniramine blocks histamine H1 receptors to reduce allergic symptoms, while phenylephrine acts as an alpha-1 adrenergic agonist to constrict blood vessels and reduce nasal congestion.","indications":["Allergic rhinitis with nasal congestion","Urticaria and pruritus associated with allergic reactions","Upper respiratory allergy symptoms"],"catalyst":""},{"name":"glucosamine sulfate /chondroitin sulfate - capsules","genericName":"glucosamine sulfate /chondroitin sulfate - capsules","slug":"glucosamine-sulfate-chondroitin-sulfate-capsules","phase":"phase_3","mechanism":"Glucosamine sulfate and chondroitin sulfate work together to provide substrates for cartilage matrix synthesis and may reduce cartilage degradation in osteoarthritis.","indications":["Osteoarthritis, particularly knee osteoarthritis"],"catalyst":""},{"name":"glucosamine sulfate /chondroitin sulfate - sachet","genericName":"glucosamine sulfate /chondroitin sulfate - sachet","slug":"glucosamine-sulfate-chondroitin-sulfate-sachet","phase":"phase_3","mechanism":"Glucosamine sulfate and chondroitin sulfate are thought to help maintain healthy joints by promoting cartilage health and reducing inflammation.","indications":["Osteoarthritis"],"catalyst":""},{"name":"Baycuten N®","genericName":"Baycuten N®","slug":"baycuten-n","phase":"phase_3","mechanism":"Baycuten N is a topical combination product containing a corticosteroid and an antimicrobial agent that reduces inflammation and prevents bacterial infection in skin conditions.","indications":["Inflammatory skin conditions with secondary bacterial infection or infection risk (e.g., eczema, dermatitis, impetigo)"],"catalyst":""},{"name":"Brompheniramine + pseudoephedrine","genericName":"Brompheniramine + pseudoephedrine","slug":"brompheniramine-pseudoephedrine","phase":"marketed","mechanism":"Brompheniramine blocks histamine H1 receptors to reduce allergic symptoms, while pseudoephedrine stimulates alpha-adrenergic receptors to constrict nasal blood vessels and relieve congestion.","indications":["Allergic rhinitis with nasal congestion","Urticaria and pruritus associated with allergies","Upper respiratory allergy symptoms"],"catalyst":""},{"name":"Candicort®","genericName":"Candicort®","slug":"candicort","phase":"phase_3","mechanism":"Candicort is a topical corticosteroid that reduces inflammation and suppresses immune responses in affected skin areas.","indications":["Inflammatory and pruritic dermatological conditions (e.g., eczema, dermatitis, psoriasis)"],"catalyst":""},{"name":"Canesten®","genericName":"Canesten®","slug":"canesten","phase":"marketed","mechanism":"Canesten inhibits fungal cell membrane synthesis by blocking ergosterol production through inhibition of lanosterol 14α-demethylase.","indications":["Vaginal candidiasis","Dermatophyte infections (tinea pedis, tinea corporis, tinea cruris)","Cutaneous candidiasis","Pityriasis versicolor"],"catalyst":""},{"name":"Combodart®","genericName":"Combodart®","slug":"combodart","phase":"phase_3","mechanism":"Combodart combines dutasteride (a 5-alpha reductase inhibitor) and tamsulosin (an alpha-1A adrenergic receptor antagonist) to reduce prostate size and improve urinary symptoms in benign prostatic hyperplasia.","indications":["Benign prostatic hyperplasia with lower urinary tract symptoms"],"catalyst":""},{"name":"Cosamin DS®","genericName":"Cosamin DS®","slug":"cosamin-ds","phase":"phase_3","mechanism":"Cosamin DS provides glucosamine and chondroitin sulfate to support cartilage structure and reduce joint degradation in osteoarthritis.","indications":["Osteoarthritis pain and joint function"],"catalyst":""},{"name":"DNN.22.17.036","genericName":"DNN.22.17.036","slug":"dnn-22-17-036","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Motore","genericName":"Motore","slug":"motore","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Nizoral®","genericName":"Nizoral®","slug":"nizoral","phase":"marketed","mechanism":"Nizoral inhibits fungal cytochrome P450 enzymes, disrupting ergosterol synthesis in the fungal cell membrane and causing cell death.","indications":["Seborrheic dermatitis (topical formulation)","Dandruff (topical formulation)","Tinea corporis, tinea pedis, tinea cruris (topical formulation)","Pityriasis versicolor (topical formulation)","Systemic fungal infections (oral formulation, historical use)"],"catalyst":""},{"name":"Placebo (for Voltaren)","genericName":"Placebo (for Voltaren)","slug":"placebo-for-voltaren","phase":"phase_3","mechanism":"A placebo has no active pharmacological mechanism; it produces therapeutic effects through psychological and psychophysiological processes.","indications":["Control arm in Phase 3 clinical trial for Voltaren (diclofenac) indication"],"catalyst":""},{"name":"Product CM9241GRU","genericName":"Product CM9241GRU","slug":"product-cm9241gru","phase":"phase_3","mechanism":"CM9241GRU is a drug that targets the renin-angiotensin system.","indications":["Hypertension"],"catalyst":""},{"name":"Product DNN.65.21.005","genericName":"Product DNN.65.21.005","slug":"product-dnn-65-21-005","phase":"phase_3","mechanism":"This drug is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes","Heart failure"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-06","type":"deal","source":"Valor International","summary":"EMS outbids competitors with R$3.2bn deal for Medley - Valor International","headline":"EMS outbids competitors with R$3.2bn deal for Medley","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE5iM1BsYkE4YUNwN01lVDN3WjVvaWtsSHd4eWhvaF8tcWw2MlN2U3l0OWFOY0VJdHRrVWVxeVh4VFlEYWQ5akFrVURuSlBqSGV6NG9nZEV5bGE5Zkszb21tQk5qUndPdXZRSU9XRmdMblRDQUxfQTB5UTFiS21fNmc?oc=5","date":"2025-11-20","type":"deal","source":"Healthcare Radius","summary":"InstaPill partners with Aché to co-develop oral dispersing tablets - Healthcare Radius","headline":"InstaPill partners with Aché to co-develop oral dispersing tablets","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxNQUtRVEtoNFBSbnpzcXZ2YjRCX1JadHBGZk1JakFibUF3Z0h6YVpiRDNpT3A0UEFwOUNHVzBNY2VjaC1xVnJXZkdSR0Fsc0lXSGU5bUF6UXRjY1lxY1FLUDNXLTY5cEJfSThFaENqcm9WQ0xzQUo5MVZkQmlkX1YtNFR6UE50SkFnall2N21BYlBmbTJGOGhibzNXeG9EcldBTDZRVVp4ckUzWlk0QUhyVkM3S19FSjl1U2J0dkxqVFFCY1RpSEtlY0lzNjNmazVlbnROd0RTWUxLc2x2bnlXc1NnRndXbENFeW4yUm9GcVhIWURS?oc=5","date":"2025-11-19","type":"deal","source":"BioSpectrum India","summary":"InstaPill partners with Aché to expand access to advanced oral dispersing tablet solutions across Latin America - BioSpectrum India","headline":"InstaPill partners with Aché to expand access to advanced oral dispersing tablet solutions across Latin America","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-17","type":"deal","source":"Express Pharma","summary":"InstaPill partners with Aché to expand access to ODT solutions across Latin America - Express Pharma","headline":"InstaPill partners with Aché to expand access to ODT solutions across Latin America","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2019-04-05","type":"pipeline","source":"Express Pharma","summary":"Japan's Takeda invites Brazilian pharmaceutical firms to bid for Latam business: Sources - Express Pharma","headline":"Japan's Takeda invites Brazilian pharmaceutical firms to bid for Latam business: Sources","sentiment":"neutral"}],"patents":[],"drugCount":17,"phaseCounts":{"marketed":8,"phase_3":9},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}